Clinical trial for Infertility, Female
Official title Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
ClinicalTrials.gov ID: NCT07128394
What this study is testing
What is Recombinant Luteinizing Hormone (rLH)?
Recombinant Luteinizing Hormone (rLH) is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for infertility, female.
Also referred to as lutropin alfa, Luveris.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether giving extra luteinizing hormone helps make embryos better in IVF patients who have too little LH during a long GnRH‑agonist treatment.
- Who it's for
- You may be able to join if you are a woman with infertility who is having IVF and has low LH levels during treatment.
- What's involved
- You will receive either a small dose of luteinizing hormone or the usual care. You will have regular visits and blood tests to check hormone levels and embryo quality.
- Time commitment
- The study lasts until the embryo is created, with several visits during the IVF cycle and follow‑up to monitor safety.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 37, women only
You may be able to join if
- Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)...
- Serum luteinizing hormone (LH) level \<0.5 U/L after pituitary downregulation.
- Written informed consent provided prior to participation.
You likely can't join if
- Polycystic ovary syndrome (PCOS). History of recurrent implantation failure (RIF). Presence of endometriosis or adenomyosis.
- Chromosomal abnormalities in either partner. Systemic diseases such as uncontrolled hypertension, diabetes, thyroid disorders, or autoimmune diseases.
- Contraindications to ovarian stimulation medications or pregnancy.
The study team makes the final eligibility decision.
Where it is enrolling
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 37 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Nanjing, Jiangsu, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.